EA201992812A1 - Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери - Google Patents
Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотериInfo
- Publication number
- EA201992812A1 EA201992812A1 EA201992812A EA201992812A EA201992812A1 EA 201992812 A1 EA201992812 A1 EA 201992812A1 EA 201992812 A EA201992812 A EA 201992812A EA 201992812 A EA201992812 A EA 201992812A EA 201992812 A1 EA201992812 A1 EA 201992812A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- releasing hormone
- blood loss
- menstrual blood
- gonadotropine
- diagrams
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515232P | 2017-06-05 | 2017-06-05 | |
| PCT/EP2018/064767 WO2018224497A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992812A1 true EA201992812A1 (ru) | 2020-05-21 |
Family
ID=62636157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992812A EA201992812A1 (ru) | 2017-06-05 | 2018-06-05 | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11759464B2 (https=) |
| EP (2) | EP3634419B1 (https=) |
| JP (2) | JP7292566B2 (https=) |
| KR (1) | KR102884301B1 (https=) |
| CN (1) | CN110996957A (https=) |
| AU (2) | AU2018280741B2 (https=) |
| CA (1) | CA3066188A1 (https=) |
| DK (1) | DK3634419T3 (https=) |
| EA (1) | EA201992812A1 (https=) |
| ES (1) | ES3018358T3 (https=) |
| FI (1) | FI3634419T3 (https=) |
| HR (1) | HRP20250390T1 (https=) |
| HU (1) | HUE070907T2 (https=) |
| MX (2) | MX2023013582A (https=) |
| PL (1) | PL3634419T3 (https=) |
| PT (1) | PT3634419T (https=) |
| SG (1) | SG11201911599XA (https=) |
| WO (1) | WO2018224497A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| SG11201911599XA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| AU2018419533A1 (en) | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| EP3829584A4 (en) * | 2018-08-01 | 2022-06-08 | Abbvie Inc. | DOSAGE SCHEDULES FOR ELAGOLIX |
| CA3117092A1 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| SG11202104053TA (en) * | 2018-11-07 | 2021-05-28 | ObsEva SA | Compositions and methods for the treatment of estrogen-dependent disorders |
| AU2020325721A1 (en) * | 2019-08-08 | 2022-03-03 | ObsEva S.A. | GnRH antagonists for the treatment of estrogen-dependent disorders |
| AU2020325655B2 (en) * | 2019-08-08 | 2025-09-11 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of estrogen-dependent disorders |
| KR20210155350A (ko) | 2020-06-15 | 2021-12-22 | 한상왕 | 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| KR102738115B1 (ko) | 2024-03-25 | 2024-12-05 | 한상왕 | 자궁근종 예방, 개선 또는 치료용 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109171B2 (en) * | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| PL1939204T6 (pl) * | 2005-10-19 | 2024-03-25 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne |
| JP5337261B2 (ja) * | 2010-02-10 | 2013-11-06 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の塩及びその結晶 |
| WO2014042176A1 (ja) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| UA123114C2 (uk) | 2016-08-08 | 2021-02-17 | Кіссеі Фармасьютікал Ко., Лтд. | СПОСІБ ЛІКУВАННЯ ЕНДОМЕТРІОЗУ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНІЛ]-2,4-ДІОКСО-1,2,3,4-ТЕТРАГІДРОТІЄНО[3,4-d]ПІРИМІДИН-5-КАРБОНОВОЮ КИСЛОТОЮ |
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| SG11201911599XA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| SG11202104053TA (en) | 2018-11-07 | 2021-05-28 | ObsEva SA | Compositions and methods for the treatment of estrogen-dependent disorders |
-
2018
- 2018-06-05 SG SG11201911599XA patent/SG11201911599XA/en unknown
- 2018-06-05 PT PT187319769T patent/PT3634419T/pt unknown
- 2018-06-05 MX MX2023013582A patent/MX2023013582A/es unknown
- 2018-06-05 JP JP2019566909A patent/JP7292566B2/ja active Active
- 2018-06-05 EP EP18731976.9A patent/EP3634419B1/en active Active
- 2018-06-05 EP EP24221894.9A patent/EP4509173A3/en active Pending
- 2018-06-05 MX MX2019014482A patent/MX2019014482A/es unknown
- 2018-06-05 HU HUE18731976A patent/HUE070907T2/hu unknown
- 2018-06-05 ES ES18731976T patent/ES3018358T3/es active Active
- 2018-06-05 CA CA3066188A patent/CA3066188A1/en active Pending
- 2018-06-05 CN CN201880050807.2A patent/CN110996957A/zh active Pending
- 2018-06-05 DK DK18731976.9T patent/DK3634419T3/da active
- 2018-06-05 AU AU2018280741A patent/AU2018280741B2/en active Active
- 2018-06-05 FI FIEP18731976.9T patent/FI3634419T3/fi active
- 2018-06-05 PL PL18731976.9T patent/PL3634419T3/pl unknown
- 2018-06-05 WO PCT/EP2018/064767 patent/WO2018224497A1/en not_active Ceased
- 2018-06-05 HR HRP20250390TT patent/HRP20250390T1/hr unknown
- 2018-06-05 EA EA201992812A patent/EA201992812A1/ru unknown
- 2018-06-05 KR KR1020197038980A patent/KR102884301B1/ko active Active
- 2018-06-05 US US16/619,702 patent/US11759464B2/en active Active
-
2023
- 2023-03-20 JP JP2023043718A patent/JP7485815B2/ja active Active
- 2023-09-11 US US18/244,773 patent/US20240000785A1/en active Pending
-
2024
- 2024-03-14 AU AU2024201694A patent/AU2024201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102884301B1 (ko) | 2025-11-11 |
| MX2019014482A (es) | 2020-08-17 |
| EP4509173A3 (en) | 2025-06-04 |
| HRP20250390T1 (hr) | 2025-05-23 |
| AU2024201694A1 (en) | 2024-04-04 |
| PL3634419T3 (pl) | 2025-06-09 |
| US20200179390A1 (en) | 2020-06-11 |
| US20240000785A1 (en) | 2024-01-04 |
| JP2020522525A (ja) | 2020-07-30 |
| US11759464B2 (en) | 2023-09-19 |
| JP7485815B2 (ja) | 2024-05-16 |
| HUE070907T2 (hu) | 2025-07-28 |
| DK3634419T3 (da) | 2025-03-31 |
| CN110996957A (zh) | 2020-04-10 |
| JP2023078315A (ja) | 2023-06-06 |
| JP7292566B2 (ja) | 2023-06-19 |
| EP4509173A2 (en) | 2025-02-19 |
| AU2018280741A1 (en) | 2020-01-30 |
| EP3634419B1 (en) | 2025-01-29 |
| FI3634419T3 (fi) | 2025-05-02 |
| AU2018280741B2 (en) | 2023-12-21 |
| PT3634419T (pt) | 2025-04-04 |
| ES3018358T3 (es) | 2025-05-16 |
| EP3634419A1 (en) | 2020-04-15 |
| KR20200024797A (ko) | 2020-03-09 |
| MX2023013582A (es) | 2024-04-16 |
| CA3066188A1 (en) | 2018-12-13 |
| WO2018224497A1 (en) | 2018-12-13 |
| SG11201911599XA (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992812A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения миомы матки и уменьшения менструальной кровопотери | |
| MX2009005398A (es) | Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf. | |
| WO2020094698A3 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| FI4374878T3 (fi) | Karbetosiinia käsittävä farmaseuttinen koostumus | |
| EA202090577A2 (ru) | Соматотропный гормон пролонгированного действия и способы его получения | |
| NO20056251L (no) | Pyrimidin-2,4-dionderivater som gonadotropin-frigjorende hormon reseptor antagonist | |
| EA201690212A8 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| EP4335497A3 (en) | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases | |
| EA202090258A3 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| EA201990249A1 (ru) | Применение и режим дозирования терапевтических агентов при эндометриозе | |
| RU2009120992A (ru) | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции | |
| NZ601684A (en) | Salt of fused heterocyclic derivative and crystal thereof | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| EA201691008A1 (ru) | 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения | |
| EA201891608A1 (ru) | Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| EA201891610A1 (ru) | Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| EA201891612A1 (ru) | Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| DK1885333T3 (da) | Farmaceutisk formulering af apomorphin til bukkal indgivelse | |
| WO2010099003A3 (en) | Compositions and methods for visualizing and eliminating cancer stem cells | |
| WO2021023877A3 (en) | Compositions and methods for the treatment of estrogen-dependent disorders | |
| EA201170004A1 (ru) | Использование антагонистов h4-гистаминовых рецепторов для лечения послеоперационных спаек |